Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …
tremendous success in treating cancer, although success still remains limited to a fraction of …
Life histories of myeloproliferative neoplasms inferred from phylogenies
N Williams, J Lee, E Mitchell, L Moore, EJ Baxter… - Nature, 2022 - nature.com
Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the
timing of driver mutations and subsequent clonal dynamics is limited,–. Here, using whole …
timing of driver mutations and subsequent clonal dynamics is limited,–. Here, using whole …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Calreticulin and cancer
Calreticulin (CALR) is an endoplasmic reticulum (ER)-resident protein involved in a
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …
spectrum of cellular processes. In healthy cells, CALR operates as a chaperone and Ca2+ …
[HTML][HTML] Classification and personalized prognosis in myeloproliferative neoplasms
J Grinfeld, J Nangalia, EJ Baxter… - … England Journal of …, 2018 - Mass Medical Soc
Background Myeloproliferative neoplasms, such as polycythemia vera, essential
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied …
[HTML][HTML] The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
T Barbui, J Thiele, H Gisslinger, HM Kvasnicka… - Blood cancer …, 2018 - nature.com
The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …